News and Press Releases
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
23 January 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 23, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
ACG to Showcase Sustainable Packaging Innovations at Pharmapack Paris 2025
Welcomes Jochen Scheil as Head of Global Sales for ACG Packaging Materials 21 January 2025 -- Paris, France -- ACG, the world’s leading supplier of integrated solutions for the pharmaceutical...
Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 21, 2025
GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITHPOTENTIAL IN MULTIPLE INFLAMMATORY DISEASES
11 January 2025 – Foster City, California, US and Ballerup, Denmark – Gilead Sciences, Inc. (Nasdaq: GILD) andLEO Pharmatoday announced a strategic partnership to accelerate the development and commercialization of...
Category: Pharmaceutical
Posted: January 13, 2025
Gilead and Leo Pharma Enter into Strategic Partnership to Accelerate Development of Oral STAT6 Program with Potential in Multiple Inflammatory Diseases
Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 11, 2025
DeanHouston Appoints New Director of Hygienic Markets
Jeff Blease brings more than 31 years of industry experience 8 January 2025 -- Kentucky, US -- DeanHouston, a business-first marketing firm that excels at creating meaningful communication strategies for...
Category: Other
Posted: January 8, 2025
Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors
Mr. Satter’s Extensive Investment, Company-Building, and Transaction Experience Strengthens Alzheon’s Board Leadership Valiltramiprosate/ALZ-801 Has Potential to Become the First Oral Agent to Slow Alzheimer’s Pathology in Patients APOLLOE4 Pivotal Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 7, 2025
IDDI Announces New Leadership to Drive Growth and Innovation
Tim Davis appointed as new Chief Executive Officer and Jeremy Edwards named the new Chief Commercial Officer 7 January 2025 -- Ottignies, Belgium -- International Drug Development Institute (IDDI), a...
Category: Clinical Trials, Other, Pharmaceutical
Posted: January 7, 2025
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 2, 2025
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
4 December 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2024
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics
Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities 29 October 2024 -- New York, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: October 29, 2024
CluePoints Appoints Richard Young as Chief Strategy Officer
28 October 2024 -- Pennsylvania, US -- RBQM innovator CluePoints has today announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 28, 2024
Coronado Research Limited announce appointment of Professor Jennifer Visser-Rogers as Chief Scientific Officer
24 October 2024 -- London, UK -- Coronado Research announced today that Professor Jennifer Visser-Rogers has been appointed as Chief Scientific Officer. Jennifer brings with her a broad portfolio of...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 24, 2024
3PBIOVIAN strengthens its leadership team with the appointment of a Business Development Director for Advanced Therapies
This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team 9 October 2024 -- Noáin, Spain...
Category: Drug Delivery, Other, Pharmaceutical
Posted: October 9, 2024
Mosaic Therapeutics appoints Dr Barry Davies as CSO
Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform. 7...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 7, 2024
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR
